• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Molecular Glue Revolution: TenAces Biosciences Unveils AI-Powered Drug Discovery Platform

by Syed Hamza Sohail 01/30/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of TenAces Biosciences.
  • TenAces is a startup developing a novel approach to discover new molecular glue therapies, leveraging machine learning to enhance development of treatments for a range of conditions.

Revolutionizing Molecular Glue Discovery with AI-Driven Targeted Protein Degradation

TenAces, originating from AION Labs’ fifth startup challenge, is developing an AI platform focused on identifying natural protein interactions for targeted protein degradation. This innovative solution aims to streamline the discovery of molecular glue therapies, departing from the traditional serendipitous discovery method. TenAces employs machine learning to analyze interactions, protein pairs, and multi-dimensional features, predicting new molecular glues. 

What sets TenAces apart is its unique integration of biology into machine learning algorithms, utilizing multiple feedback loops with wet lab validations to enhance predictive capabilities. The founding team includes Chief AI Officer Dr. Tomer Sidi, an expert in deep learning and bioinformatics, and Bioinformatics Lead Dr. Chen Lior, with a strong background in bioinformatics and experimental biology, both contributing to the groundbreaking approach.

“We are developing a novel solution for targeted protein degradation by enabling the identification of optimal E3 degraders and designing molecular glues for removal of disease-causing proteins. With some 85% of target proteins currently undruggable, we can potentially address a wide range of diseases,” said Arnout Schepers, PhD, Founder and CEO of TenAces. “AION Labs has proven invaluable in facilitating the establishment of TenAces. The support of our pharma partners has been integral in shaping the company, providing the essential resources and guidance necessary to develop and eventually commercialize solutions that can facilitate more effective treatment.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

Viz.ai Launches Viz Pulmonary™ Suite: AI-Powered Workflows for COPD, Lung Nodules, and PE

PathAI Partners to Deploy First AI-Powered Biospecimen Solutions

Roche Acquires PathAI to Automate Cancer Diagnostics in $1B Deal

Vocal Biomarkers: Helping Clinicians Detect What Patients Hesitate to Share

Vocal Biomarkers: Helping Clinicians Detect What Patients Hesitate to Share

Aidoc Secures $150M to Accelerate Enterprise-Scale Clinical AI Across 2,000 Hospitals

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

OpenAI Launches ChatGPT for Clinicians: Free AI Documentation and Research Tool for Verified Physicians

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

IKS Health Acquires TruBridge for Rural EHR and RCM Solutions Expansion

UT Austin is Building the Nation's First 'AI-Native' Hospital, Backed by $750M

Why UT Austin is Building an ‘AI-Native’ Hospital from Scratch

The Medtech Pitch Deck Casino: Why Hype Still Wins, and How Scrutiny Could Improve Everyone’s Odds

The Casino Model: Why Medtech VCs Are Betting Billions on Unproven AI

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |